Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
Get Alerts MIST Hot Sheet
Join SI Premium – FREE
MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company presentation at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024 at 8:45 am ET.
The webcast is available to watch both live and replay for approximately 90 days following the presentation in the News & Events section of Milestone’s website. www.milestonepharma.com
About Milestone PharmaceuticalsMilestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company’s focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone’s lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat highly symptomatic episodic attacks associated with PSVT and AFib-RVR.
Contact:Kim Fox, Vice President, Communications, [email protected]
Investor RelationsChris Calabrese, [email protected]Kevin Gardner, [email protected]
Source: Milestone Pharmaceuticals Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HERISM Relaunches with a New SKIN Series and an AI Skin-MatchWing App, Building on Seven Years in Skincare
- AI Memory & Storage: The 5th GMIF2026 Innovation Summit Successfully Concludes in Shenzhen
- The Palate Global Continues to Advance Charitable Initiatives in Indonesia
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share